Contrary to the findings of Świechowski et al. [39] and Joković et al. [40], Schosser et al. [60] reviewed studies on patients with treatment-resistant depression and found no significant association between their metabolic profiles linked to the CYP2C19 gene and treatment response or remission in both the GSRD and the STAR*D study samples. The gene discussed is CYP2C19; the disease is depressive symptom measurement.